跳转到主内容

疫苗之外华海药业有大事 高血压药版“三聚氰胺”初见端倪! 加拿大400万病人拟议集体诉讼 路透社指事件可能追溯到2012年!

深蓝财经 深蓝财经 · 2018.07.24 22:15 · 3.6万阅读
作者: 国际投行研究报告

来源:国际投行研究报告


全国人民为疫苗而痛!但对于全国,甚至全球11亿高血压病人来说,最近以来最痛苦的是自己是否吃了用浙江华海药业原料药制剂生产的高血压用药!

但昨天晚上,华海药业的澄清公告着实让小编震惊!公告开宗明义说“近期有网络自媒体就公司关于缬沙坦原料药的未知杂质中发现极微量基因毒性杂质的事情进行了各种不实的报道,严重误导了投资者”。随便梳理一下,小编觉得华海药业的逻辑有些混乱,而且,小编翻了一下外电,加拿大的病人已经拟向5家加拿大药企具体诉讼,代工的是华海药业,更加让小编觉得蒙羞的是,路透社报道,这事可能早在2012年就开始了!其实这才是华海药业最需要澄清的事实!"澄清公告混乱逻辑高血压版“三聚氰胺”见端倪

看起来在疫苗和自身问题的双重打击下,华海药业是有点急了。所以昨天晚上匆忙发了一个澄清公告。


二、澄清声明:

1、基于分析检测能力的提升,公司在发现NDMA杂质后,主动告知了客户和相关监管部门。

2、NDMA杂质是使用公司现行注册工艺正常生产过程中产生的微量工艺杂质,公司的工艺变更均经过各国药监部门批准,在符合法规标准的前提下合规生产。

3、在公司发现该杂质时,各国监管部门尚未对该杂质制定可接受控制限度的行业标准。

4、根据相关文献,世界卫生组织(WHO)所属机构IARC(国际癌症研究机构)将NDMA归为2A类致癌物质,2A类是指在动物实验中有相应数据支持,但对人类致癌性证据有限的物质。该类杂质在啮齿类动物的致癌性受到时间和剂量的双重因素影响,对人体的影响尚未明确。

5、相关国家的公告中指出,“使用含有NDMA杂质的缬沙坦制剂产品的患者不会有严重的健康风险,长期使用可能会使癌症风险略有增加”(挪威官方公告);“在欧3/3洲已经对潜在危险进行了初步科学评估,目前可以排除严重威胁。”(奥地利官方公告)。作为预防措施,各国对使用公司缬沙坦原料药生产的制剂产品进行召回。

6、根据FDA官网显示,2017年度,美国FDA共针对1075次药品召回发出了报告(https://www.accessdata.fda.gov/scripts/ires/index.cfm#tabNav_advancedSearch)

总结起来,就是这个东西是我们主动检测出来报告的,吃了也死不了人,小编真的奇怪,主动发现有毒就不是问题了?华海药业支支吾吾的说我确实有问题,但这是我自己发言并告诉洋人的,不是洋人发现的。这是什么理论呢,难道自己发现的就没毒?

凌通社

5分钟前:各位一定记得当年某酒中检测中三聚氰胺的报道,记得当年酒类检测出三聚氰胺的时候,是这样解释的,我们的检测中没这个标准,如今,华海药业再次因为中国药典中没这检测项目.....关键是,根据哈三联的说明,入厂检验标准为华海药业提供的YBH01882012和《中国药典》2015年版二部进行全项检验,该标准中未列入“亚硝基二甲胺”检验项目。哈三联称,公司缬沙坦分散片严格按照《药品生产质量管理规范》(2010年版)要求进行生产。华海药业系公司三家缬沙坦原料药供应商之一,从华海药业采购的缬沙坦原料药,入厂检验标准为华海药业提供的YBH01882012和《中国药典》2015年版二部进行全项检验,该标准中未列入“亚硝基二甲胺”检验项目。公司将对召回产品进行“亚硝基二甲胺”杂质检测,本次召回不涉及其他供应商供应缬沙坦原料药生产的缬沙坦分散片及公司的其他产品。

凌通社

5分钟前:那么,华海药业是怎么突然想到要检测这个指标了呢?小编觉得逻辑有点乱。其实,一切公关和澄清的要义是说清楚,说真话!并且真心道歉,毕竟是药品,你和全球11亿高血压病人相关。最新:加拿大400万病人第一个集体诉讼已来华海药业准备好了吗?

在华海药业的公告中,除了澄清之外,对于股民关心的损失问题只字不提,事实上,大家都清楚,这一损失肯定包括具体的召回的损失,时间的损失,信用的损失,更大的可能是接着来的集体诉讼。而加拿大CTV电视台报道,第一个具体诉讼已经在襁褓中了。医药类诉讼在海外是非常吓人的。


针对五家加拿大制药公司提起的集体诉讼提起诉讼,指控该公司可能在制造药品方面存在疏忽,并对其在中国的供应商进行原材料质量控制测试。

7月10日,加拿大卫生部召回了使用缬沙坦成分的五个仿制品牌的28种血压药物。生产缬沙坦的中国公司报告了N-亚硝基二甲胺(NDMA)的污染,国际癌症研究机构将其列为可能的人类致癌剂。

涉及污染的中国公司浙江华海制药没有回应CTV新闻的评论请求。

此次召回可能会影响到已经开具这些药物的440万加拿大人。一项拟议的集体诉讼指控五家加拿大公司-Teva Canada Ltd.,Sandoz Canada Inc.,Pro Doc Limitee,Sanis Health Inc.和Sivem Pharmaceuticals ULC-可能未对其产品进行充分测试。

“你服用医生给你的药丸。你在药房买了它。你不认为会发生任何事情,“病人卡拉詹姆斯告诉CTV新闻。“这简直令人难以置信。”

詹姆斯多年来一直服用一种被召回的药物,现在已成为拟议诉讼的一部分。她说当药房打电话表明她的处方被召回时,她感到震惊。

“我很害怕,”她说。“我只是不知道该做什么或想什么。我能想到的是:'我最好尽快去找我的医生。'“

虽然詹姆斯已经能够找到另一种处方,但似乎其他人可能没那么幸运。报告显示此次召回导致全球众多处方药短缺。

加拿大药剂师协会已经列出了一份清单,以帮助医生和其他处方医生为其客户寻找其他选择。

关于召回的几个未解决的问题仍然存在,包括有多少药物受到影响以及持续多长时间。到目前为止,关于致癌剂如何进入药物治疗的唯一报告表明它是“制造过程”的结果。

“我想知道的是,到目前为止我还没有听到这个问题持续了多长时间,”魁北克三河大学医学研究员Jacinthe Leclerc说。

“这些公司需要对公众保持透明,告诉他们患者可以使用多长时间的药物......以及他们将采取什么措施来防止任何进一步的问题。”

加拿大卫生部对可能受影响的人的建议:

如果含有缬沙坦,请继续服药,除非您的医生或药剂师告诉您停止服用;

联系您的医生,看看召回是否会影响您的药物;和

如果您的药物是召回的一部分,请联系您的医生讨论可能的后续步骤。

CTVNews.ca Staff

Published Sunday,July 22,2018 10:06PM EDT

A proposed class-action lawsuit has been filed against five Canadian pharmaceutical companies alleging the firms may have been negligent in their manufacturing of the drugs and in quality control testing of raw material from their supplier in China.

On July 10,Health Canada recalled

28 blood pressure medications from five generic brands that use the ingredient valsartan.The Chinese firm that produces valsartan reported a contamination with N-nitrosodimethylamine(NDMA),which the International Agency for Research on Cancer has classified as a probable human cancer causing agent.

Zhejiang Huahai Pharmaceuticals,the Chinese company involved in the contamination,did not respond to a request for comment from CTV News

Health Canada recall notice

pills

The recall could impact 4.4 million Canadians who’ve been prescribed certain medications.

The recall could impact 4.4 million Canadians who’ve been prescribed these drugs.A proposed class-action lawsuit alleges the five Canadian companies--Teva Canada Ltd.,Sandoz Canada Inc.,Pro Doc Limitee,Sanis Health Inc.and Sivem Pharmaceuticals ULC--might not have adequately tested their products.

“You take the pill your doctor gives you.You pick it up at the pharmacy.You don't think that anything is going to happen,”patient Carla James told CTV News.“It’s just unbelievable.”

James has been taking one of the recalled drugs for years and is now part of the proposed lawsuit.She says when the pharmacy called to indicate there’d been a recall on her prescription,she was shocked.


“I was terrified,”she said.“I just didn't know what to do or what to think.All I could think is:‘I better get to my doctor(as soon as possible).’”

While James has been able to find an alternative prescription,it appears others might not be so lucky.Reports suggest the recall has caused a worldwide shortage of numerous prescription medications.

The Canadian Pharmacists Association

has put together a list to help doctors and other prescribers find other options for their clients.

Several unanswered questions remain about the recall,including how many of the drugs have been impacted and for how long.The only report so far about how the cancer-causing agent got into the medications suggests it was a result of the“manufacturing process.”

“What I would like to know that I haven’t been able to hear up to now is for how long this problem has been going on,”said Jacinthe Leclerc,a medical researcher with Universite du Quebec a Trois-Rivieres.

“The companies will need to be transparent to the public,telling them for how long the potentially contaminated pills were…available to patients and what are they going to do to prevent any further problems.”

Health Canada’s advice to those who may be affected:

Continue to take your medication if it contains valsartan,unless your doctor or pharmacist has told you to stop;

Contact your doctor and see if the recall impacts your medication;and

If your medication is part of the recall,contact your doctor to discuss the possible next steps.路透社:中国心脏病药可能从2012年就销往全球


LONDON(Reuters)-A common blood pressure and heart drug manufactured in bulk by a Chinese company and sold worldwide may have contained an impurity linked to cancer since 2012,European regulators said on Tuesday.

FILE PHOTO:Guido Rasi,executive director the European Medicines Agency at his office in London January 6,2012.REUTERS/Finbarr O'Reilly/File Photo

The revelation that the problem likely dates back to changes in manufacturing processes at Zhejiang Huahai Pharmaceutical six years ago suggests many patients could potentially have been exposed to cancer risk.

The European Medicines Agency(EMA),which first raised the alarm over the Chinese supplied valsartan on July 5,said it was now working to establish how long and at what levels patients might have been exposed to the impurity known as NDMA.

伦敦(路透社)-欧洲监管机构周二表示,自2012年以来,一家中国公司大量生产并在全球范围内销售的常见血压和心脏药物可能含有与癌症有关的杂质。


文件图片:Guido Rasi,欧洲药品管理局执行董事,2012年1月6日在伦敦办公室。路透社/Finbarr O'Reilly/文件照片

该问题可能追溯到六年前浙江华海药业制造流程的变化,这表明许多患者可能已经面临癌症风险。

NDMA,or N-nitrosodimethylamine,is classified as a probable human carcinogen.Based on results from laboratory tests,it may cause cancer with long-term use.

“It is still too early to provide information on the longer term risk NDMA may have posed for patients.EMA has made this aspect of the review a priority and will update the public as soon as new information becomes available,”the agency said.

EU authorities have been recalling medicines containing valsartan from Zhejiang Huahai over the past two weeks and the EMA said such medicines should no longer be available in pharmacies.

The U.S.Food and Drug Administration also took action to recall affected valsartan-containing medicines on Friday.

Zhejiang Huahai has already acknowledged that there was an impurity in some of its valsartan,which it said had sales of$50 million in 2017.Officials at the company could not immediately be reached for comment outside of regular business hours on the fact the problem might date back to 2012.

The EMA said NDMA was an unexpected impurity that was not detected by routine tests carried out by Zhejiang Huahai,adding that the manufacturing changes introduced in 2012 were believed to have produced NDMA as a by-product.

欧洲药品管理局(EMA)于7月5日首次对中国供应的缬沙坦发出警报,称该公司目前正在努力确定患者可能暴露于NDMA杂质的时间和程度。

NDMA或N-亚硝基二甲胺被归类为可能的人类致癌物。根据实验室检测结果,长期使用可能会导致癌症。

“现在提供有关NDMA可能对患者构成的长期风险的信息还为时尚早。EMA已将审查的这一方面作为优先事项,并将在新信息公布后立即更新公众,“该机构表示。

过去两周,欧盟当局一直在召回浙江华海含有缬沙坦的药物,EMA称这些药物不再适用于药店。

浙江华海已经承认其部分缬沙坦中存在杂质,据称其2017年的销售额为5000万美元。该公司的官员无法在正常营业时间之外立即联系到来评论该问题的日期可能回溯到2012年这一事实

EMA表示,NDMA是浙江华海进行的常规测试未发现的意外杂质,并认为2012年引入的制造业变化被认为是NDMA作为副产品。

发稿编辑: 易尔
0 0
微博

评论 (0)

登录 后可发表评论

暂无评论,快来抢沙发吧

深蓝财经
深蓝财经 深蓝号

深蓝财经,影响有影响力的人。创立于2011年,发源于深蓝财经记者社区,关注资本市场、公司价值、财经传媒行业,是国内领先的财经新媒体。

本文系作者 深蓝财经 授权深蓝财经发表,并经深蓝财经编辑,转载请注明出处、作者和本文链接。

本内容来源于深蓝财经,文章内容仅供参考、交流、学习,不构成投资建议。

想和千万深蓝财经用户分享你的新奇观点和发现,点击这里投稿。 创业或融资寻求报道,点击这里。

意见反馈